Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Gupta, Poonam
- A Review on Diabetes and Its Management
Abstract Views :1015 |
PDF Views:0
Authors
Affiliations
1 Saroj Institute of Technology and Management, Ahimamau P.O. Arjunganj Sultanpur Road, Lucknow- 226002,Uttar Pradesh, IN
1 Saroj Institute of Technology and Management, Ahimamau P.O. Arjunganj Sultanpur Road, Lucknow- 226002,Uttar Pradesh, IN
Source
Asian Journal of Pharmaceutical Research, Vol 3, No 1 (2013), Pagination: 28-33Abstract
The current approach to the treatment of both type 1 and type 2 diabetes is to achieve the best possible glucose control. Past clinical trials have shown that glycemia plays a key role in the prevention of both macro- and microvascular complications. During the past 20 years, a number of new medications to control blood glucose have been introduced, and new approaches to the use of older medications have been developed. Weight and diabetes, especially type 2 diabetes, are closely related. Obesity is a major risk factor for the development of type 2 diabetes, and the current increase in obesity in our society has fueled a major increase in the expression of this disease. Not only does weight, through the mechanism of insulin resistance, aggravate hyperglycemia, it also increases the risk for hypertension, hyperlipidemia, and other conditions that lead to cardiovascular disease.Keywords
Glycemia, Obesity, Hyperglycemia, Hypertension, Hyperlipidemia
References
- Cambon-Thomsen, A.; Rial-Sebbag, E.; Knoppers, B. M. (2007). "Trends in ethical and legal frameworks for the use of human biobanks". European Respiratory Journal 30 (2): 373–382. doi:10.1183/09031936.00165006. PMID 17666560.
- Agency for Healthcare Research and Quality (March 2011). "Oral Diabetes Medications for Adults with Type 2 Diabetes. An Update". Comparative Effectiveness Review number 27 (AHRQ Pub. No. 11-EHC038-1). Retrieved 28 November 2012.
- Bennett, W. L.; Maruthur, N. M.; Singh, S.; Segal, J. B.; Wilson, L. M.; Chatterjee, R.; Marinopoulos, S. S.; Puhan, M. A. et al. (2011). "Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations". Annals of internal medicine 154 (9): 602–613. doi:10.1059/0003-4819-154-9-201105030-00336. PMID 21403054.
- Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to Medicine (Step-Up Series). Hagerstwon, MD: Lippincott Williams and Wilkins. ISBN 0-7817-7153-6.
- Eurich; McAlister, FA; Blackburn, DF; Majumdar, SR; Tsuyuki, RT; Varney, J; Johnson, JA (2007). "Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.". BMJ (Clinical research ed.) 335 (7618): 497. doi:10.1136/bmj.39314.620174.80. PMC 1971204. PMID 17761999.
- Fimognari; Pastorelli, R; Incalzi, RA (2006). "Phenformininduced lactic acidosis in an older diabetic patient: a recurrent drama (phenformin and lactic acidosis).". Diabetes Care 29 (4): 950–1. doi:10.2337/diacare.29.04.06.dc06-0012. PMID 16567854.
- Verdonck; Sangster, B; Van Heijst, AN; De Gischolar_main, G; Maes, RA (1981). "Buformin concentrations in a case of fatal lactic acidosis.” Diabetologia 20 (1): 45–6. doi:10.1007/BF01789112. PMID 7202882.
- Nissen; Wolski, K (2007). "Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.". The New England Journal of Medicine 356 (24): 2457–71. doi:10.1056/NEJMoa072761. PMID 17517853. Lay summary – Associated Press (May 21, 2007).
- Wood, Shelley (2007-07-31). "FDA Advisory Panels Acknowledge Signal of Risk With Rosiglitazone, but Stop Short of Recommending Its Withdrawal". Heartwire. Retrieved 2007-09-21.
- Ajjan; Grant, PJ (2008). "The cardiovascular safety of rosiglitazone.” Expert opinion on drug safety 7 (4): 367–76. doi:10.1517/14740338.7.4.367. PMID 18613801.
- Erdmann; Dormandy, JA; Charbonnel, B; Massi-Benedetti, M; Moules, IK; Skene, AM; Proactive, Investigators (2007). "The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.". Journal of the American College of Cardiology 49 (17): 1772–80. doi:10.1016/j.jacc.2006.12.048. PMID 17466227.
- Rendell (2004). "Advances in diabetes for the millennium: drug therapy of type 2 diabetes.". MedGenMed : Medscape general medicine 6 (3 Suppl): 9. PMC 1474831. PMID 15647714.
- Konno; Tortorelis, DG; Fullerton, SA; Samadi, AA; Hettiarachchi, J; Tazaki, H (2001). "A possible hypoglycaemic effect of maitake mushroom on type 2 diabetic patients.” Diabetic Medicine 18 (12): 1010. doi:10.1046/j.1464-5491.2001.00532- 5.x. PMID 11903406.
- Hong; Xun, M; Wutong, W (2007). "Anti-diabetic effect of an alpha-glucan from fruit body of maitake (Grifola frondosa) on KK-Ay mice.". The Journal of pharmacy and pharmacology 59
- (4): 575–82. doi:10.1211/jpp.59.4.0013. PMID 17430642. 15. Kubo; Aoki, H; Nanba, H (1994). "Anti-diabetic activity present in the fruit body of Grifola frondosa (Maitake). I.". Biological and Pharmaceutical Bulletin 17 (8): 1106–10. doi:10.1248/bpb.17.1106. PMID 7820117.
- Lo, HC; Hsu, TH; Chen, CY (2008). "Submerged culture mycelium and broth of Grifola frondosa improve glycemic responses in diabetic rats.” The American journal of Chinese medicine 36 (2): 265–85. doi:10.1142/S0192415X0800576X. PMID 18457360.
- Yeh, GY; Eisenberg, DM, Kaptchuk, TJ, Phillips, RS (2003 Apr). "Systematic review of herbs and dietary supplements for glycemic control in diabetes.". Diabetes Care 26 (4): 1277–94. doi:10.2337/diacare.26.4.1277. PMID 12663610.
- Kirkham, S; Akilen, R, Sharma, S, Tsiami, A (2009 Dec). "The potential of cinnamon to reduce blood glucose levels in patients with type 2 diabetes and insulin resistance.". Diabetes, obesity and metabolism 11 (12): 1100–13. doi:10.1111/j.1463- 1326.2009.01094.x. PMID 19930003.
- Balk, EM; Tatsioni, A; Lichtenstein, AH; Lau, J; Pittas, AG (2007). "Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials". Diabetes Care 30 (8): 2154–63. doi:10.2337/dc06-0996. PMID 17519436.
- Cooke DW, Plotnick L (November 2008). "Type 1 diabetes mellitus in pediatrics". Pediatr Rev 29 (11): 374–84; quiz 385. doi:10.1542/pir.29-11-374. PMID 18977856.
- Emerging Risk Factors Collaboration (2010). "Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies". The Lancet 375 (9733): 2215–22. doi:10.1016/S0140-6736(10)60484- 9. PMC 2904878. PMID 20609967.
- Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C (2011). "Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials". BMJ 343: d4169. doi:10.1136/bmj.d4169. PMC 3144314. PMID 21791495.
- Risérus U, Willet W (January 2009). "Dietary fats and prevention of type 2 diabetes". Progress in Lipid Research 48 (1): 44–51. doi:10.1016/j.plipres.2008.10.002. PMC 2654180. PMID 19032965.
- Unless otherwise specified, reference is: Table 20-5 in Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson. Robbins Basic Pathology. Philadelphia: Saunders. ISBN 1-4160-2973-7. 8th edition.
- Sattar N, Preiss, D, Murray, HM, Welsh, P, Buckley, BM, de Craen, AJ, Seshasai, SR, McMurray, JJ, Freeman, DJ (February 2010). "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials". The Lancet 375 (9716): 735–42. doi:10.1016/S0140-6736(09)61965-6. PMID 20167359.
- Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: World Health Organization. 2006. p. 21. ISBN 978-92-4-159493-6.
- Vijan, S (March 2010). "Type 2 diabetes". Annals of Internal Medicine 152 (5): ITC31-15. doi:10.1059/0003-4819-152-5- 201003020-01003. PMID 20194231.
- Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL (August 2001). "Postchallenge hyperglycemia and mortality in a national sample of U.S. adults". Diabetes Care 24 (8): 1397–402. doi:10.2337/diacare.24.8.1397. PMID 11473076.
- Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, Booker L, Yazdi H. "Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose". Summary of Evidence Report/Technology Assessment, No. 128. Agency for Healthcare Research and Quality. Retrieved 2008-07-20.
- Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL (2010). "Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults". N. Engl. J. Med. 362 (9): 800–11. doi:10.1056/NEJMoa0908359. PMC 2872990. PMID 20200384.
- Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (December 2005). "Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes". The New England Journal of Medicine 353 (25): 2643–53. doi:10.1056/NEJMoa052187. PMC 2637991. PMID 16371630
- Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C: Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 12:661–668, 2004
- Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG: Amylin replacement with pramlintide as an adjuct to insulin therapy improves longterm glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 21:1204–1212, 2004
- A Review-Miracle of Nanotechnology in Cosmetics
Abstract Views :212 |
PDF Views:1
Authors
Affiliations
1 Azad Institute of Pharmacy & Research, Azadpur, Adjacent CRPF Camp, Bijnour, Lucknow-226002, UP, IN
2 AMA Herbal Laboratories Pvt. Ltd., 352/116-G, Talkatora Road, P.O. Rajajipuram, Lucknow-226017, UP, IN
3 Saroj Institute of Technology and Management, Ahimamau P.O. Arjunganj, Sultanpur Road, Lucknow-226002, Uttar Pradesh, IN
1 Azad Institute of Pharmacy & Research, Azadpur, Adjacent CRPF Camp, Bijnour, Lucknow-226002, UP, IN
2 AMA Herbal Laboratories Pvt. Ltd., 352/116-G, Talkatora Road, P.O. Rajajipuram, Lucknow-226017, UP, IN
3 Saroj Institute of Technology and Management, Ahimamau P.O. Arjunganj, Sultanpur Road, Lucknow-226002, Uttar Pradesh, IN
Source
Asian Journal of Pharmaceutical Research, Vol 4, No 1 (2014), Pagination: 16-23Abstract
The cosmetics industry is large, with sales over $200 billion. Personal care products are a growing part of the chemical industry worldwide. Compared to industries involved in nanotechnology, it is modest. Nanotechnology entered the field of comsetics and health products nearly 40 years ago with moisturing creams that used liposomes, a vesical of phospholipid layers with an aquaeus core. The applications of nanotechnology and nanomaterials can be found in many cosmetic products including moisturizers, hair care products, make up and sunscreen. Nanomaterials are now being used in leading cosmetic products, most commonly as chemicals used to give the protection in sunscreens. Encapsulation and carrier systems like liposomes, nanoemulsions, microemulsions or lipid nanoparticles serve to transport agents to deeper skin layers. Nanoparticles of titan dioxide and zinc oxide are used as UV filters in sunscreens. There is little evidence supporting the principle that smaller particles have greater effects on the skin or other tissues or produce novel toxicities relative to micro-sized materials. Overall, the current weight of evidence suggests that nano-materials such as nano-sized vesicles or TiO2 and ZnO nanoparticles currently used in cosmetic preparations or sunscreens pose no risk to human skin or human health, although other Nano particle may have properties that warrant safety evaluation on a case-by-case basis before human use. Recently, concerns over the safety of such nanocosmetics are raised and have forced the cosmetic industries to limit the use of nanotechnology in cosmetics and for enforcing laws to undergo a full-fledged safety assessment before they enter into the market. In this review, emphasis is made on the types of nanomaterials used in cosmetics by the various cosmetic brands, the potential risks caused by them both to human life and also to the environment and what all regulations have been undertaken or can be taken to overcome them.Keywords
Liposomes, Nanomaterials, Nanoemulsions, Micro Emulsions, Lipid Nanoparticles.- A Review-Biomedical Engineering-Present and Future Prospective
Abstract Views :292 |
PDF Views:1
Authors
Affiliations
1 Saroj Institute of Technology & Management, Ahimamau P.O. Arjunganj, Sultanpur Road, Lucknow, IN
1 Saroj Institute of Technology & Management, Ahimamau P.O. Arjunganj, Sultanpur Road, Lucknow, IN
Source
Asian Journal of Pharmaceutical Research, Vol 3, No 4 (2013), Pagination: 202-206Abstract
Biomedical engineering is the application of engineering principles and design concepts to medicine and biology for healthcare purposes. This field seeks to close the gap between engineering and medicine: It combines the design and problem solving skills of engineering with medical and biological sciences to advance healthcare treatment, including diagnosis, monitoring, and therapy. Much of the work in biomedical engineering consists of research and development, spanning a broad array of subfields. Prominent biomedical engineering applications include the development of biocompatible prostheses, various diagnostic and therapeutic medical devices ranging from clinical equipment to micro-implants, common imaging equipment such as MRIs and EEGs, regenerative tissue growth, pharmaceutical drugs and therapeutic biological. But more often, sub-disciplines within BME are classified by their association(s) with other more established engineering fields, which can include:
• Biochemical-BME, based on Chemical engineering - often associated with biochemical, cellular, molecular and tissue engineering, biomaterials, and biotransport.
• Bioelectrical-BME, based on Electrical engineering and Computer Science - often associated with bioelectrical and neural engineering, bioinstrumentation, biomedical imaging, and medical devices. This also tends to encompass optics and optical engineering - biomedical optics, bioinformatics, imaging and related medical devices.
• Biomechanical-BME, based on Mechanical engineering - often associated with biomechanics, biotransport, medical devices, and modeling of biological systems, like soft tissue mechanics.
RoHS seeks to limit the dangerous substances in circulation in electronics products, in particular toxins and heavy metals, which are subsequently released into the environment when such devices are recycled. IEC 60601-1-11 (2010) must now be incorporated into the design and verification of a wide range of home use and point of care medical devices along with other applicable standards in the IEC 60601 3rd edition series.
Keywords
Diagnosis, Monitoring, Therapy, Biocompatible Prostheses, RoHS, IEC 60601-1-11.- A Review-Living with Butterfly Skin Disease
Abstract Views :159 |
PDF Views:1
Authors
Mohd. Yaqub Khan
1,
Poonam Gupta
1,
Bipin Bihari
1,
Vinod Kumar Singh
1,
Sanjay Kumar Yadav
1,
Aparna Misra
1
Affiliations
1 Saroj Institute of Technology & Management, Ahimamau P.O. Arjunganj, Sultanpur Road, Lucknow-226002, IN
1 Saroj Institute of Technology & Management, Ahimamau P.O. Arjunganj, Sultanpur Road, Lucknow-226002, IN